[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IT1404380B1 - USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES - Google Patents

USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES

Info

Publication number
IT1404380B1
IT1404380B1 ITMI2011A000213A ITMI20110213A IT1404380B1 IT 1404380 B1 IT1404380 B1 IT 1404380B1 IT MI2011A000213 A ITMI2011A000213 A IT MI2011A000213A IT MI20110213 A ITMI20110213 A IT MI20110213A IT 1404380 B1 IT1404380 B1 IT 1404380B1
Authority
IT
Italy
Prior art keywords
complications
diabetes
treatment
combination
active ingredients
Prior art date
Application number
ITMI2011A000213A
Other languages
Italian (it)
Inventor
Giuseppe Remuzzi
Piero Ruggenenti
Bruno Pietro Imbimbo
Giuseppe Lauria
Iliev Ilian Petrov
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Priority to ITMI2011A000213A priority Critical patent/IT1404380B1/en
Publication of ITMI20110213A1 publication Critical patent/ITMI20110213A1/en
Application granted granted Critical
Publication of IT1404380B1 publication Critical patent/IT1404380B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ITMI2011A000213A 2010-02-16 2011-02-14 USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES IT1404380B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ITMI2011A000213A IT1404380B1 (en) 2010-02-16 2011-02-14 USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2010A000236A IT1398168B1 (en) 2010-02-16 2010-02-16 USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES.
ITMI2011A000213A IT1404380B1 (en) 2010-02-16 2011-02-14 USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES

Publications (2)

Publication Number Publication Date
ITMI20110213A1 ITMI20110213A1 (en) 2011-08-17
IT1404380B1 true IT1404380B1 (en) 2013-11-22

Family

ID=42270257

Family Applications (2)

Application Number Title Priority Date Filing Date
ITMI2010A000236A IT1398168B1 (en) 2010-02-16 2010-02-16 USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES.
ITMI2011A000213A IT1404380B1 (en) 2010-02-16 2011-02-14 USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ITMI2010A000236A IT1398168B1 (en) 2010-02-16 2010-02-16 USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES.

Country Status (3)

Country Link
ES (1) ES2387054B2 (en)
FR (1) FR2956976B1 (en)
IT (2) IT1398168B1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733911B1 (en) * 1995-05-09 1998-05-29 Takeda Chemical Industries Ltd PHARMACEUTICAL COMPOSITION FOR RENAL OR CARDIOVASCULAR DISEASES
RU2281764C2 (en) * 2000-03-17 2006-08-20 Адзиномото Ко., Инк. Medicinal agents for treatment of complications associated with diabetes mellitus and neuropathy and their using
AU2581601A (en) * 2000-12-18 2002-07-01 Novartis Ag Therapeutic combination of amlodipine and benazepril
PE20040468A1 (en) * 2002-05-17 2004-09-14 Novartis Ag ORGANIC COMPOUND COMBINATION
CA2597247A1 (en) * 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent

Also Published As

Publication number Publication date
ES2387054B2 (en) 2014-02-13
ITMI20100236A1 (en) 2011-08-17
ES2387054A1 (en) 2012-09-12
FR2956976A1 (en) 2011-09-09
ITMI20110213A1 (en) 2011-08-17
FR2956976B1 (en) 2012-08-17
IT1398168B1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
HRP20181364T8 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
PL2731947T3 (en) Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
CL2014002757A1 (en) Compounds derived from benzamide to inhibit the activity of abl1, abl2 and bcr-abl1, pharmaceutical composition; and use in the treatment of cancer.
CO6811867A2 (en) Cannabinoids for use in the treatment of neuropathic pain
CL2014001829A1 (en) Compounds derived from indolizine; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer.
MX356957B (en) Glucagon analogues.
PL2768937T3 (en) Formulations, their use as or for the manufacture of dishwashing agents and their manufacture
CL2013003372A1 (en) Compounds derived from spiro- [1,3] -oxacins and spiro- [1,4] -oxacepins, inhibitors of bace1 and / or bace2; pharmaceutical composition; procedure to prepare them; and its use in the treatment and / or prophylaxis of Alzheimer's disease and diabetes.
FR2975004B1 (en) NEW ANTI-REDNESS ACTIVE INGREDIENTS AND COSMETIC COMPOSITIONS COMPRISING THE SAME
EP2841068B8 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
HK1201047A1 (en) Skin care formulation
CL2012003322A1 (en) Compounds derived from substituted benzamide; pharmaceutical composition; and use in the treatment of cancer.
IT1402082B1 (en) INSTRUMENTS FOR THE PREPARATION OF RAVIOLI OR FILLED PASTA IN GENERAL.
CL2015001202A1 (en) Compounds derived from oxazolidin-2-one-pyrimidine; pharmaceutical composition and combination and use in the treatment of cancer.
BR112015012443A2 (en) cleansing composition, method of cleansing the human body, use of the composition and method for providing cleansing
HRP20180011T1 (en) Compounds for use in the treatment of filariasis
CL2014001323A1 (en) Compounds derived from 3-phenyl-isoquinolin-1 (2h) -one, parp-1 inhibitors; preparation procedure; pharmaceutical composition; and use in the treatment of cancer.
CL2013001445A1 (en) Compounds derived from diphenylamine; Pharmaceutical composition and use in the treatment of inflammatory diseases, such as cancer.
IT1398875B1 (en) COMPOSITIONS CONTENTS L. MUCOSAE FOR MEDICAL USE.
HK1214771A1 (en) Formulations for use in the treatment of skin conditions
IT1404380B1 (en) USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES
CO6801770A2 (en) Use of secnidazole in the treatment of dental infections
HK1172568A1 (en) Soluble pharmaceutical forms of n,n-diaminodiphenyl sulphone for optimum use in the treatment of various diseases nn-
CO6801760A2 (en) Use of 3-carboxy-n-ethyl-n, n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease